Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Mar;32(2):e34.
doi: 10.3802/jgo.2021.32.e34. Epub 2021 Feb 8.

Current status and future directions of ovarian cancer prognostic models

Yusuke Kobayashi  1 , Kouji Banno  2 , Daisuke Aoki  2
Affiliations
Editorial

Current status and future directions of ovarian cancer prognostic models

Yusuke Kobayashi et al. J Gynecol Oncol. 2021 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Comment on

References

    1. Kim M, Suh DH, Lee KH, Eom KY, Lee JY, Lee YY, et al. Major clinical research advances in gynecologic cancer in 2019. J Gynecol Oncol. 2020;31:e48. - PMC - PubMed
    1. Foo T, George A, Banerjee S. PARP inhibitors in ovarian cancer: an overview of the practice-changing trials. Genes Chromosomes Cancer. 2020 - PubMed
    1. Kehoe S. FIGO staging in ovarian carcinoma and histological subtypes. J Gynecol Oncol. 2020;31:e70. - PMC - PubMed
    1. Irodi A, Rye T, Herbert K, Churchman M, Bartos C, Mackean M, et al. Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data. BJOG. 2020;127:1409–1420. - PubMed
    1. Lu HY, Tai YJ, Chen YL, Chiang YC, Hsu HC, Cheng WF. Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients. J Gynecol Oncol. 2021;32:e18. - PMC - PubMed

Publication types